Equities

Cytokinetics Inc

Cytokinetics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)52.28
  • Today's Change-2.30 / -4.21%
  • Shares traded3.02m
  • 1 Year change+38.56%
  • Beta0.7447
Data delayed at least 15 minutes, as of Jun 06 2024 21:15 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.

  • Revenue in USD (TTM)3.75m
  • Net income in USD-530.60m
  • Incorporated1997
  • Employees423.00
  • Location
    Cytokinetics Inc350 Oyster Point BoulevardSOUTH SAN FRANCISCO 94080United StatesUSA
  • Phone+1 (650) 624-3000
  • Fax+1 (650) 624-3010
  • Websitehttps://cytokinetics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Immunitybio Inc302.00k-600.96m4.44bn628.00------14,701.54-1.05-1.050.0005-1.020.0008--0.1677480.89-161.65-112.76-946.50-316.07-----199,138.70-37,700.74---1.925.32--159.1767.62-40.00--18.48--
Krystal Biotech Inc95.95m57.16m4.57bn229.0085.045.7172.0647.641.881.883.3828.020.1385----418,991.308.25-11.508.78-12.0194.25--59.57-492.8512.42--0.00------107.81--39.49--
Apellis Pharmaceuticals Inc524.07m-417.27m4.76bn702.00--17.85--9.09-3.46-3.464.332.200.57880.57473.50746,538.40-46.09-73.88-57.28-90.0386.47---79.62-326.493.02-39.710.6087--425.83--18.94------
Madrigal Pharmaceuticals Inc0.00-444.28m5.03bn376.00--5.74-----23.08-23.080.0041.130.00----0.00-62.81-62.09-73.92-74.81--------9.39--0.1201-------26.50--132.01--
BridgeBio Pharma Inc218.60m-538.26m5.24bn550.00------23.98-3.23-3.231.29-5.610.2964----397,449.10-74.13-72.44-90.19-89.7298.9194.41-250.09-1,225.66---11.482.53---88.02---33.67---40.94--
Ionis Pharmaceuticals Inc776.62m-384.77m5.48bn927.00--18.48--7.06-2.67-2.675.402.030.2750.37981.52837,777.80-13.62-6.30-15.20-7.4498.7298.75-49.54-21.237.28--0.8114--34.105.60-35.80--11.83--
Organon & Co6.35bn1.05bn5.49bn10.00k5.23113.694.250.86434.084.0824.710.18760.56032.184.24634,700.009.2416.5311.7920.9759.0465.1216.5026.791.152.360.99458.251.44-8.5211.56-13.8320.72--
Cytokinetics, Inc.3.75m-530.60m5.56bn423.00------1,481.39-5.40-5.400.0382-3.780.0044--4.088,869.98-62.50-43.14-69.19-47.22-----14,141.74-540.47---15.262.78---92.04-24.89-35.30--9.76--
Halozyme Therapeutics, Inc.862.99m318.80m5.64bn373.0018.3231.6814.066.532.422.426.541.400.48741.344.422,313,644.0018.0118.2219.2221.9778.5079.0536.9439.365.36966.620.89410.0025.6240.4339.31--26.82--
Summit Therapeutics Inc0.00-116.03m6.10bn105.00--137.90-----0.1657-0.16570.000.0630.00----0.00-53.76-77.32-59.38-86.35-------20,989.46---118.810.6934---100.00---680.54---4.84--
Exelixis Inc1.85bn205.05m6.32bn1.31k33.543.0127.443.420.64660.64665.847.210.6213.127.781,409,653.006.908.867.829.9195.7096.3011.1015.433.41--0.000.0013.6016.4713.98-21.343.98--
Revolution Medicines Inc4.57m-484.27m6.32bn411.00--3.66--1,385.00-3.76-3.760.03510.460.0031--2.2912,079.37-32.48-29.76-34.18-32.59-----10,606.04-606.93----0.00---67.27-10.50-75.46--38.82--
Blueprint Medicines Corp282.21m-288.29m6.61bn645.00--21.27--23.42-4.82-4.824.594.960.24990.35316.18430,853.40-25.53-29.92-30.68-34.0696.97---102.15-116.653.61-23.370.4352--22.2241.149.06--4.85--
Jazz Pharmaceuticals PLC3.84bn330.79m6.63bn2.80k21.711.796.781.734.854.8555.4958.650.34360.64285.781,372,634.002.991.483.361.6289.5388.798.694.261.901.870.6070.004.7815.19285.14-1.49-20.04--
Data as of Jun 06 2024. Currency figures normalised to Cytokinetics Inc's reporting currency: US Dollar USD

Institutional shareholders

53.97%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Mar 202411.19m10.70%
The Vanguard Group, Inc.as of 31 Mar 20249.73m9.31%
Fidelity Management & Research Co. LLCas of 31 Mar 20249.69m9.27%
T. Rowe Price Investment Management, Inc.as of 31 Mar 20245.12m4.90%
SSgA Funds Management, Inc.as of 31 Mar 20244.52m4.32%
Bank of America, NA (Private Banking)as of 31 Mar 20244.24m4.05%
Wellington Management Co. LLPas of 31 Mar 20243.98m3.81%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 20242.87m2.75%
Marshall Wace LLPas of 31 Mar 20242.56m2.45%
RTW Investments LPas of 31 Mar 20242.53m2.42%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.